Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy
Pharmacoeconomic study of different preparations of botulinum toxin type A used for the treatment of cerebral palsy in terms of health of the Russian Federation was conducted. The aim of this study was to determine the most appropriate therapy of cerebral palsy from the pharmacoeconomic point of view. We compared three regimens: botulinum toxin type A - Dysport® in combination with standard therapy, botulinum toxin type A - Botox® in combination with standard therapy and standard therapy without the use of botulinum toxin. It should be noted that centrally acting muscle relaxant (Baclofen) was used in standard therapy, but BTA in this treatment scheme is not used to eliminate unwanted relaxation of the muscles. As a result, it was found that the regimen Dysport®+standard therapy has the lowest cost-effectiveness ratio (11 608 rubles) in comparison with drug therapy Botox®+standard therapy (12 879 rubles) and standard therapy with a centrally acting muscle relaxant without BTA (25 222 rubles) by the end of 2 years of treatment. According to the budget impact analysis at the end of 2 years for 1 patient the scheme Dysport®+standard therapy was the least expensive form of therapy (1 079 500 rubles) in comparison with therapy Botox®+standard therapy (1 159 085 rubles) and standard therapy with a centrally acting muscle relaxant without BTA (1 210 678 rubles).
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link: Ugrekhelidze D.T., Kulikov A.Yu. Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy // Pharmacoeconomics: theory and practice. - 2015. - Vol.3, №3. - P.71-78 DOI: https://doi.org/10.30809/phe.3.2015.5